A UK-based startup looks to beat Spark's Luxturna at its own game with programmable cell platform for eye disease
Spark’s Luxturna made waves in 2017 when it was approved to treat inherited retinal degradation by replacing the mutated RPE65 gene with a normal copy. But instead of replacing a faulty gene to regain function, what if scientists could reprogram whole cells in vivo?
On Tuesday, a UK-based startup reeled in $17 million to pursue just that.
Mogrify set out in 2016 to pioneer a new class of in vivo reprogramming therapies in ophthalmology and use that same technology to transform the way ex vivo cell therapies are developed. The company first closed a Series A round in 2019. And now, investors are tacking on another $17 million, bringing the expanded round to $33 million in total.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.